NASDAQ · ARTV
Healthcare · Biotechnology
$11.94
Up+$0.17 (+1.44%)
Updated Aug 28, 2026, 12:59 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ARTV closed at $11.94 after 21 trading sessions, up 14.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $11.72 | $12.08 | $11.56 | $11.94 | 218.27K |
| Aug 26, 2026 | $11.75 | $11.93 | $11.60 | $11.77 | 262.56K |
| Aug 25, 2026 | $11.60 | $11.91 | $11.53 | $11.77 | 266.36K |
| Aug 24, 2026 | $10.83 | $11.70 | $10.49 | $11.52 | 307.24K |
| Aug 21, 2026 | $11.26 | $11.5995 | $10.7601 | $10.93 | 199.42K |
| Aug 20, 2026 | $11.50 | $11.5802 | $10.9305 | $11.14 | 319.08K |
| Aug 19, 2026 | $11.69 | $11.85 | $11.21 | $11.70 | 458K |
| Aug 18, 2026 | $11.52 | $12.00 | $11.52 | $11.68 | 261.93K |
| Aug 17, 2026 | $11.45 | $11.84 | $11.10 | $11.74 | 288.78K |
| Aug 14, 2026 | $11.24 | $11.585 | $10.80 | $11.45 | 264.42K |
| Aug 13, 2026 | $11.59 | $11.7588 | $11.22 | $11.30 | 253.29K |
| Aug 12, 2026 | $11.74 | $12.10 | $11.51 | $11.53 | 275.2K |
| Aug 11, 2026 | $11.18 | $12.27 | $11.02 | $11.78 | 456.61K |
| Aug 10, 2026 | $11.12 | $11.46 | $11.02 | $11.22 | 178.96K |
| Aug 7, 2026 | $11.625 | $11.98 | $10.75 | $11.27 | 214.69K |
| Aug 6, 2026 | $11.52 | $12.06 | $11.38 | $11.58 | 321.64K |
| Aug 5, 2026 | $11.15 | $11.74 | $10.58 | $11.59 | 548.57K |
| Aug 4, 2026 | $10.60 | $11.29 | $10.40 | $11.07 | 411.22K |
| Aug 3, 2026 | $10.00 | $10.81 | $9.90 | $10.76 | 572.39K |
| Jul 31, 2026 | $10.25 | $10.406 | $9.6749 | $10.10 | 361.92K |
| Jul 30, 2026 | $10.00 | $10.5934 | $10.00 | $10.43 | 230.87K |
The latest Smart Investors Daily articles mentioning ARTV.
ARTV research
Company profile and research snapshot.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Needham | Buy | — |
| May 12, 2026 | Needham | Buy | — |
| May 11, 2026 | Cantor Fitzgerald | Overweight | — |
| May 11, 2026 | Wedbush | Outperform | — |
| May 8, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 18, 2026
Artiva Biotherapeutics advances AlloNK NK cell therapy for refractory rheumatoid arthritis; early data shows 71% ACR50 and safety. Click for more on ARTV stock.
Yahoo · Aug 6, 2026
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versu
Benzinga · Aug 6, 2026
-SEC Filing
Benzinga · Jun 10, 2026
Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 results and raising FY26 sales guidance.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARTV.
